Trump Gets Experimental COVID Tx, Now at Walter Reed

President Trump, who announced he tested positive for COVID-19 early Friday morning, was headed to Walter Reed National Military Medical Center in the late afternoon for tests and possibly treatment.

Bloomberg reported that Trump would be staying at Walter Reed for “the next few days,” citing a statement from the White House.

An earlier statement from White House physician Sean Conley, DO, said the president had received “a single 8 gram dose of Regeneron’s polyclonal antibody cocktail,” which was completed “without incident.”

Regeneron had released topline results for its investigational REGN-COV2 antibody cocktail on Tuesday: the phase I/II/III trial showed the drug “reduced viral load and the time to alleviate symptoms in non-hospitalized patients with COVID-19,” as well as showing positive trends towards reducing medical visits.

But the product has not received FDA approval emergency use authorization yet, making it truly investigational. Some physicians on Twitter were puzzled that the president was using it. Jeremy Faust, MD, of Brigham and Women’s Hospital in Boston, tweeted that the president’s team either “can’t read basic medical literature” or “can read basic medical literature, but can’t overrule what [the president] is telling them to do” — or the president’s condition is far more serious than reported, and they are trying everything.

Trump is also receiving zinc, vitamin D, famotidine (Pepcid AC), melatonin, and a daily aspirin, according to Conley. It wasn’t clear whether these were started as COVID therapy or were simply part of his regular regimen. Conley also didn’t mention the president’s daily statin that had been reported on previously.

Conley said the president is “fatigued, but in good spirits,” and added that First Lady Melania Trump, who also tested positive, has “a mild cough and headache.”

Earlier on Friday, AP reported that officials saying masks will still not be mandatory at the White House, describing them as a “personal choice.”

On Saturday morning, Conley released another memo, saying in consultation with specialists, doctors “have elected to initiate remdesivir therapy” for Trump. The president completed his first dose and is “resting comfortably,” Conley said.

Remdesivir is an investigational antiviral that received emergency use authorization in May. In a randomized trial of hospitalized patients, time to recovery was significantly lower, though differences in mortality estimates between the two groups were non-significant.

Reports from CNN via Twitter on Friday cited a Trump adviser who claimed the president was “having some trouble breathing”; however, Conley said the president “is not requiring any supplemental oxygen.”

Conley said he recommended that the president be admitted for “further monitoring” in consultation with specialists from Walter Reed and Johns Hopkins University.

Last Updated October 03, 2020

  • author['full_name']

    Molly Walker is an associate editor, who covers infectious diseases for MedPage Today. She has a passion for evidence, data and public health. Follow

Source Article

Recommended Articles